New drug price controversy looms as Biogen stuns payers with Spinraza's $750K sticker — analyst
One prominent analyst believes we may soon see a new drug price controversy erupt, only this one will have nothing to do with price gouging on an old therapy.
The drug is Spinraza, the newly approved pioneering therapy for rare cases of spinal muscular atrophy from Biogen and its partners at Ionis. Earlier this week Biogen priced the drug at about $750,000 for the first year and half that for each year after, or $1.5 million over three years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
